Canada Markets open in 6 hrs 35 mins

Today's Research Reports on Oncolytics Biotech, Delivra, Aptose Biosciences and ProMIS Neurosciences

NEW YORK, NY / ACCESSWIRE / January 28, 2019 / The Market Wealth Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://marketwealthreport.com and get exclusive access to our numerous research reports and market updates.

The Market Wealth Report Initiates Coverage on:

Oncolytics Biotech Inc.
https://marketwealthreport.com/report/ONC.TO/

Delivra Corp.
https://marketwealthreport.com/report/DVA.V/

Aptose Biosciences Inc.
https://marketwealthreport.com/report/APS.TO/

ProMIS Neurosciences, Inc.
https://marketwealthreport.com/report/PMN.TO/

Oncolytics Biotech's stock jumped 3.45% Friday, to close the day at $2.70. The stock recorded a trading volume of 8,599 shares, which was below its three months average volume of 27,780 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 2.26 - 10.65. The share price has gained 19.47% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.71 is lower than its 200-day moving average of $4.44. Shares of Oncolytics Biotech have gained approximately 7.57 percent year-to-date.

Access The Market Wealth's Oncolytics Biotech Inc. Research Report:
https://marketwealthreport.com/report/ONC.TO/

On Friday, shares of Delivra recorded a trading volume of 70,338 shares, which was above the three months average volume of 32,357 shares. The stock ended the day flat at $0.39. The share price has fallen 22% from its 52 week high with a 52 week trading range of 0.23 - 0.50. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.29 is lower than its 200-day moving average of $0.33. Shares of Delivra have gained approximately 59.18 percent year-to-date.

Access The Market Wealth's Delivra Corp. Research Report:
https://marketwealthreport.com/report/DVA.V/

Aptose Biosciences' stock moved 2.97% higher Friday, to close the day at $2.77. The stock recorded a trading volume of 48,107 shares, which was above its three months average volume of 36,835 shares. In the last year, Aptose Biosciences' shares have traded in a range of 2.34 - 5.97. The share price has gained 18.38% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $2.86 is lower than its 200-day moving average of $3.27. Shares of Aptose Biosciences have gained approximately 6.54 percent year-to-date.

Access The Market Wealth's Aptose Biosciences Inc. Research Report:
https://marketwealthreport.com/report/APS.TO/

On Friday, shares of ProMIS Neurosciences recorded a trading volume of 95,454 shares, which was below the three months average volume of 199,245 shares. The stock ended the day 9.8% higher at $0.28. The share price has fallen 61.64% from its 52 week high with a 52 week trading range of 0.19 - 0.73. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.25 is lower than its 200-day moving average of $0.29. Shares of ProMIS Neurosciences have gained approximately 3.7 percent year-to-date.

Access The Market Wealth's ProMIS Neurosciences, Inc. Research Report:
https://marketwealthreport.com/report/PMN.TO/

Our Actionable Research on Oncolytics Biotech Inc. (TSX:ONC.TO), Delivra Corp. (TSXV:DVA.V), Aptose Biosciences Inc. (TSX:APS.TO) and ProMIS Neurosciences, Inc. (TSX:PMN.TO) can be downloaded free of charge at The Market Wealth Report.

The Market Wealth Report

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

The Market Wealth Report has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of MarketWealthReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketWealthReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketwealthreport.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

The Market Wealth Report, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@marketwealthreport.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Market Wealth Report